Radioimmunotherapy of non-Hodgkin's lymphoma

From the 'magic bullets' to 'radioactive magic bullets'

Murthy R. Chamarthy, Scott C. Williams, Renee M. Moadel

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Radioimmunotherapy (RIT†) of lymphoma with Zevalin and Bexxar was approved by FDA in 2002 and 2003, respectively, for the treatment of relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. In 2009, Zevalin was also approved for consolidation therapy in patients with follicular non-Hodgkin's lymphoma that achieve a partial or complete response to first-line chemotherapy. For follicular lymphoma patients, the overall response and progression-free survival rates have significantly improved since the implementation of RIT. The predominant complication of RIT is hematological toxicity that is usually manageable. There are ongoing trials to further define the expanding role of RIT as first line or concomitant therapy in the treatment of lymphoma as well as for certain antibiotic resistant infections and aggressive malignancies. There is also growing interest in the development of newer protocols for increased and more uniform dose delivery resulting in better outcomes and improved patient survival. This review will primarily focus on the role of RIT in treatment of non-Hodgkin's lymphoma, which is of established clinical utility and FDA approved. The mechanism of RIT, available radionuclides and pharmacokinetics, therapy administration, clinical utility and toxicities, and future directions would be discussed.

Original languageEnglish (US)
Pages (from-to)391-407
Number of pages17
JournalYale Journal of Biology and Medicine
Volume84
Issue number4
StatePublished - Dec 2011

Fingerprint

Radioimmunotherapy
Magic
Non-Hodgkin's Lymphoma
Toxicity
Pharmacokinetics
Chemotherapy
Radioisotopes
Consolidation
Refractory materials
Follicular Lymphoma
Cells
Anti-Bacterial Agents
Lymphoma
Therapeutics
B-Cell Lymphoma
Disease-Free Survival
ibritumomab tiuxetan
Survival Rate
Drug Therapy
Survival

Keywords

  • Alpha particle
  • Auger
  • Beta particle
  • Bexxar
  • Biodistribution
  • Dosimetry
  • Hodgkin's lymphoma
  • Immunotherapy
  • Lymphoma
  • Monoclonal antibody
  • Non-Hodgkin's lymphoma
  • Radioimmunotherapy
  • Rituximab
  • Y-90
  • Zevalin

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Radioimmunotherapy of non-Hodgkin's lymphoma : From the 'magic bullets' to 'radioactive magic bullets'. / Chamarthy, Murthy R.; Williams, Scott C.; Moadel, Renee M.

In: Yale Journal of Biology and Medicine, Vol. 84, No. 4, 12.2011, p. 391-407.

Research output: Contribution to journalArticle

@article{776f0387d948435fa0285d0b48bc3187,
title = "Radioimmunotherapy of non-Hodgkin's lymphoma: From the 'magic bullets' to 'radioactive magic bullets'",
abstract = "Radioimmunotherapy (RIT†) of lymphoma with Zevalin and Bexxar was approved by FDA in 2002 and 2003, respectively, for the treatment of relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. In 2009, Zevalin was also approved for consolidation therapy in patients with follicular non-Hodgkin's lymphoma that achieve a partial or complete response to first-line chemotherapy. For follicular lymphoma patients, the overall response and progression-free survival rates have significantly improved since the implementation of RIT. The predominant complication of RIT is hematological toxicity that is usually manageable. There are ongoing trials to further define the expanding role of RIT as first line or concomitant therapy in the treatment of lymphoma as well as for certain antibiotic resistant infections and aggressive malignancies. There is also growing interest in the development of newer protocols for increased and more uniform dose delivery resulting in better outcomes and improved patient survival. This review will primarily focus on the role of RIT in treatment of non-Hodgkin's lymphoma, which is of established clinical utility and FDA approved. The mechanism of RIT, available radionuclides and pharmacokinetics, therapy administration, clinical utility and toxicities, and future directions would be discussed.",
keywords = "Alpha particle, Auger, Beta particle, Bexxar, Biodistribution, Dosimetry, Hodgkin's lymphoma, Immunotherapy, Lymphoma, Monoclonal antibody, Non-Hodgkin's lymphoma, Radioimmunotherapy, Rituximab, Y-90, Zevalin",
author = "Chamarthy, {Murthy R.} and Williams, {Scott C.} and Moadel, {Renee M.}",
year = "2011",
month = "12",
language = "English (US)",
volume = "84",
pages = "391--407",
journal = "Yale Journal of Biology and Medicine",
issn = "0044-0086",
publisher = "Yale Journal of Biology and Medicine Inc.",
number = "4",

}

TY - JOUR

T1 - Radioimmunotherapy of non-Hodgkin's lymphoma

T2 - From the 'magic bullets' to 'radioactive magic bullets'

AU - Chamarthy, Murthy R.

AU - Williams, Scott C.

AU - Moadel, Renee M.

PY - 2011/12

Y1 - 2011/12

N2 - Radioimmunotherapy (RIT†) of lymphoma with Zevalin and Bexxar was approved by FDA in 2002 and 2003, respectively, for the treatment of relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. In 2009, Zevalin was also approved for consolidation therapy in patients with follicular non-Hodgkin's lymphoma that achieve a partial or complete response to first-line chemotherapy. For follicular lymphoma patients, the overall response and progression-free survival rates have significantly improved since the implementation of RIT. The predominant complication of RIT is hematological toxicity that is usually manageable. There are ongoing trials to further define the expanding role of RIT as first line or concomitant therapy in the treatment of lymphoma as well as for certain antibiotic resistant infections and aggressive malignancies. There is also growing interest in the development of newer protocols for increased and more uniform dose delivery resulting in better outcomes and improved patient survival. This review will primarily focus on the role of RIT in treatment of non-Hodgkin's lymphoma, which is of established clinical utility and FDA approved. The mechanism of RIT, available radionuclides and pharmacokinetics, therapy administration, clinical utility and toxicities, and future directions would be discussed.

AB - Radioimmunotherapy (RIT†) of lymphoma with Zevalin and Bexxar was approved by FDA in 2002 and 2003, respectively, for the treatment of relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. In 2009, Zevalin was also approved for consolidation therapy in patients with follicular non-Hodgkin's lymphoma that achieve a partial or complete response to first-line chemotherapy. For follicular lymphoma patients, the overall response and progression-free survival rates have significantly improved since the implementation of RIT. The predominant complication of RIT is hematological toxicity that is usually manageable. There are ongoing trials to further define the expanding role of RIT as first line or concomitant therapy in the treatment of lymphoma as well as for certain antibiotic resistant infections and aggressive malignancies. There is also growing interest in the development of newer protocols for increased and more uniform dose delivery resulting in better outcomes and improved patient survival. This review will primarily focus on the role of RIT in treatment of non-Hodgkin's lymphoma, which is of established clinical utility and FDA approved. The mechanism of RIT, available radionuclides and pharmacokinetics, therapy administration, clinical utility and toxicities, and future directions would be discussed.

KW - Alpha particle

KW - Auger

KW - Beta particle

KW - Bexxar

KW - Biodistribution

KW - Dosimetry

KW - Hodgkin's lymphoma

KW - Immunotherapy

KW - Lymphoma

KW - Monoclonal antibody

KW - Non-Hodgkin's lymphoma

KW - Radioimmunotherapy

KW - Rituximab

KW - Y-90

KW - Zevalin

UR - http://www.scopus.com/inward/record.url?scp=84863393240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863393240&partnerID=8YFLogxK

M3 - Article

VL - 84

SP - 391

EP - 407

JO - Yale Journal of Biology and Medicine

JF - Yale Journal of Biology and Medicine

SN - 0044-0086

IS - 4

ER -